Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma.
B7-H3
CTLA-4
Meningioma
PD-L1
PD-L2
PI3K/AKT/mTOR
brain tumor
immune checkpoint protein
immunotherapy
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
Historique:
received:
04
04
2018
revised:
24
07
2018
accepted:
13
08
2018
entrez:
15
12
2018
pubmed:
14
12
2018
medline:
14
12
2018
Statut:
epublish
Résumé
Meningioma is the most common brain tumor in adults. Surgical resection remains the primary treatment. No chemotherapy exists. However, gene mutations now could explain ~ 80% of meningioma and targeted therapies based on these are being investigated. Furthermore, with the recent discovery of PD-L1 in malignant meningioma, clinical trials using immunotherapy have commenced. Here, we report for the first time the expression profiles of immune checkpoint proteins PD-L2, B7-H3 and CTLA-4 in meningioma and their association to common gene mutations. PD-L2 and B7-H3 expression was significantly greater than all immune checkpoint proteins studied, and particularly elevated in patients with gene mutations affecting the PI3K/AKT/mTOR pathway. CTLA-4 expressing CD3+ lymphocytes were observed in atypical and malignant meningioma and tumors harboring a
Identifiants
pubmed: 30546952
doi: 10.1080/2162402X.2018.1512943
pii: 1512943
pmc: PMC6287792
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
e1512943Références
Nature. 2014 Nov 27;515(7528):563-7
pubmed: 25428504
Int J Cancer. 2005 Nov 20;117(4):538-50
pubmed: 15912538
Neuro Oncol. 2017 Nov 29;19(12):1588-1598
pubmed: 28531331
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Clin Cancer Res. 2017 Jun 15;23(12):3158-3167
pubmed: 28619999
Immunol Rev. 2009 May;229(1):12-26
pubmed: 19426212
PLoS One. 2013 Oct 01;8(10):e74798
pubmed: 24098347
Lancet Oncol. 2017 May;18(5):682-694
pubmed: 28314689
J Invest Dermatol. 2013 Aug;133(8):2050-8
pubmed: 23474948
Cancer Discov. 2016 Feb;6(2):202-16
pubmed: 26645196
PLoS One. 2017 Jan 31;12(1):e0171146
pubmed: 28141831
Cancer Immunol Res. 2017 Nov;5(11):1046-1055
pubmed: 29038297
J Neurooncol. 2016 Dec;130(3):543-552
pubmed: 27624915
Brain Tumor Pathol. 2016 Oct;33(4):237-247
pubmed: 27624470
Acta Neuropathol. 2013 Mar;125(3):351-8
pubmed: 23404370
Cancer Treat Rev. 2014 Jul;40(6):750-9
pubmed: 24613036
Oncol Lett. 2014 Jun;7(6):2019-2022
pubmed: 24932282
Neurosurgery. 1988 Aug;23(2):175-9
pubmed: 3185876
PLoS One. 2015 Apr 06;10(4):e0123410
pubmed: 25844720
J Neurosurg. 1983 Jan;58(1):51-6
pubmed: 6847909
Sci Rep. 2016 Jun 08;6:27528
pubmed: 27273624
Clin Cancer Res. 2016 Jul 15;22(14):3425-3431
pubmed: 27208063
Cancer Res. 2016 Jan 15;76(2):227-38
pubmed: 26637667
Oncotarget. 2015 Mar 10;6(7):4704-16
pubmed: 25609200
Oncotarget. 2016 Feb 9;7(6):6891-901
pubmed: 26771843
J Neuroinflammation. 2015 Sep 17;12:170
pubmed: 26377554
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Nat Commun. 2016 Aug 30;7:12632
pubmed: 27572267
Lung Cancer. 2006 Aug;53(2):143-51
pubmed: 16782226
Trends Cancer. 2018 Jun;4(6):401-404
pubmed: 29860983
J Neurol Surg B Skull Base. 2014 Jun;75(3):152-8
pubmed: 25072008
J Cancer. 2017 Feb 25;8(5):816-824
pubmed: 28382144
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19458-63
pubmed: 18042703
Nat Immunol. 2001 Mar;2(3):261-8
pubmed: 11224527
Eur J Immunol. 2009 Jul;39(7):1754-64
pubmed: 19544488
Mod Pathol. 2010 Aug;23(8):1104-12
pubmed: 20495537
Am J Pathol. 2012 Nov;181(5):1749-61
pubmed: 22982440
Clin Dev Immunol. 2012;2012:656340
pubmed: 22611421
Semin Cancer Biol. 2018 Feb;48:91-103
pubmed: 28467889
Radiat Oncol. 2009 Oct 14;4:42
pubmed: 19828022
Prostate Cancer Prostatic Dis. 2017 Mar;20(1):28-35
pubmed: 27801901
J Neurosurg. 1989 Nov;71(5 Pt 1):665-72
pubmed: 2809720
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Clin Biochem. 2017 Mar;50(4-5):194-205
pubmed: 27871894
Lancet. 2017 Oct 21;390(10105):1853-1862
pubmed: 28822576
Ann Oncol. 2016 Mar;27(3):409-16
pubmed: 26681673
BMC Cancer. 2014 Aug 20;14:602
pubmed: 25139714
Science. 2013 Mar 1;339(6123):1077-80
pubmed: 23348505
Int J Cancer. 2011 Jul 15;129(2):275-84
pubmed: 20839260
Cancer Genet. 2015 Jun;208(6):345-50
pubmed: 25963524
Nat Genet. 2013 Mar;45(3):285-9
pubmed: 23334667
Neuro Oncol. 2013 Nov;15(11):1479-90
pubmed: 23978377
J Neurooncol. 2010 Sep;99(3):307-14
pubmed: 20821343